These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 7062283)

  • 1. A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist.
    Colpaert FC; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1982 Apr; 221(1):206-14. PubMed ID: 7062283
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo evidence of partial agonist activity exerted by purported 5-hydroxytryptamine antagonists.
    Colpaert FC; Niemegeers CJ; Janssen PA
    Eur J Pharmacol; 1979 Oct; 58(4):505-9. PubMed ID: 510385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation between the stimulus effects of (+)-lysergic acid diethylamide and lisuride using a three-choice, drug discrimination procedure.
    Callahan PM; Appel JB
    Psychopharmacology (Berl); 1990; 100(1):13-8. PubMed ID: 2296621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the behavioral effects of lysergic acid diethylamide, 2,5-dimethoxy-4-methylamphetamine, quipazine and lisuride by 5-hydroxytryptamine antagonists.
    Mokler DJ; Commissaris RL; Warner MR; Rech RH
    J Pharmacol Exp Ther; 1983 Dec; 227(3):557-62. PubMed ID: 6655557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice.
    Benneyworth MA; Smith RL; Barrett RJ; Sanders-Bush E
    Psychopharmacology (Berl); 2005 Jun; 179(4):854-62. PubMed ID: 15645221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats.
    Meert TF; de Haes P; Janssen PA
    Psychopharmacology (Berl); 1989; 97(2):206-12. PubMed ID: 2471220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation between the stimulus effects of l-5-hydroxytryptophan and LSD.
    Cunningham KA; Callahan PM; Appel JB
    Eur J Pharmacol; 1985 Jan; 108(2):179-86. PubMed ID: 3156756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminative stimulus properties of lysergic acid diethylamide in the monkey.
    Nielsen EB
    J Pharmacol Exp Ther; 1985 Jul; 234(1):244-9. PubMed ID: 4009503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LSD, 5-HT (serotonin), and the evolution of a behavioral assay.
    Appel JB; West WB; Buggy J
    Neurosci Biobehav Rev; 2004 Jan; 27(8):693-701. PubMed ID: 15019419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide: the role of 5-hydroxytryptamine.
    Winter JC
    J Pharmacol Exp Ther; 1978 Feb; 204(2):416-23. PubMed ID: 621672
    [No Abstract]   [Full Text] [Related]  

  • 11. Interactions of clozapine with the stimulus effects of DOM and LSD.
    Palumbo PA; Winter JC
    Pharmacol Biochem Behav; 1994 Sep; 49(1):115-20. PubMed ID: 7816860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A characterization of LSD-antagonist effects of pirenperone in the rat.
    Colpaert FC; Janssen PA
    Neuropharmacology; 1983 Aug; 22(8):1001-5. PubMed ID: 6621823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli.
    Winter JC; Eckler JR; Rabin RA
    Psychopharmacology (Berl); 2004 Mar; 172(2):233-40. PubMed ID: 14598016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The stimulus properties of LSD in C57BL/6 mice.
    Winter JC; Kieres AK; Zimmerman MD; Reissig CJ; Eckler JR; Ullrich T; Rice KC; Rabin RA; Richards JB
    Pharmacol Biochem Behav; 2005 Aug; 81(4):830-7. PubMed ID: 16005500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.
    Glennon RA; Young R; Rosecrans JA
    Eur J Pharmacol; 1983 Jul; 91(2-3):189-96. PubMed ID: 6617740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites.
    Friedman RL; Barrett RJ; Sanders-Bush E
    J Pharmacol Exp Ther; 1984 Mar; 228(3):628-35. PubMed ID: 6707913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD).
    Cunningham KA; Appel JB
    Psychopharmacology (Berl); 1987; 91(1):67-73. PubMed ID: 3103161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminative stimulus properties of lergotrile.
    Cunningham KA; Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1984 Jul; 230(1):47-52. PubMed ID: 6146709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of dopamine and serotonin in the discriminative stimulus effects of lisuride.
    White FJ; Appel JB
    J Pharmacol Exp Ther; 1982 May; 221(2):421-7. PubMed ID: 7077537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative discriminative stimulus effects of 5-methoxy-N,N-dimethyltryptamine and LSD.
    Young R; Rosecrans JA; Glennon RA
    Life Sci; 1982 Jun; 30(24):2057-62. PubMed ID: 7109835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.